Introduction
============

The commonest type of dementia, Alzheimer's disease (AD), is accompanied with chronic deterioration in cognitive function and accounts for 60--70% of dementia cases ([@B12]; [@B40]). According to a review in 2014, around 35.6 million people are suffering from AD at present, and the incidence of AD is progressively increasing with age and affects approximately 115.4 million people by the year of 2050 worldwide ([@B12]). It is generally accepted that AD is a complicated neurodegenerative disease of multiple pathologies, which mainly associated with cholinergic transmission degeneration, oxidative stress, neuroinflammation, and so on ([@B10]; [@B2]; [@B36]; [@B55]; [@B20]; [@B3]). Acetylcholinesterase (AChE) inhibitors, such as donepezil, rivastigmine and galanthamine, are preferentially prescribed for the clinical treatment of AD in the early stages ([@B29]; [@B47]; [@B28]). In addition, antioxidants and anti-inflammatory agents are also proverbially used in the adjuvant therapy of AD ([@B61]; [@B11]). However, all these agents exert limited effectiveness due to loss of efficacy gradually as the disease progress, and the medications are also associated with many toxic side effects ([@B61]; [@B23]; [@B40]). Namely, there is no available satisfactory treatment currently to cure AD or to alter its progressive course.

Harmaline (HAL) and harmine (HAR) are the abundant pharmacological β-carboline alkaloids of *Peganum harmala* L. with similar chemical structures ([@B34]). They possess a significant AChE, monoamine oxidase (MAO) and myeloperoxidase (MPO) inhibitory activities, antioxidant, anti-inflammatory, antitumor, and anti-hypertension effects, and can also affect the contents of various neurotransmitters then may lead to biochemical, physiological, and behavioral changes in animals and human beings ([@B41]; [@B13]; [@B25]; [@B21]; [@B39]; [@B4]; [@B56]; [@B33]). According to our previous studies, HAL and HAR displayed similar AChE inhibition compared to galanthamine *in vitro* ([@B60]). Moreover, the total alkaloids (28 mg/kg) of *P. harmala* primarily contain HAL and HAR exhibited the improving effect on the deficits of learning and memory induced by scopolamine and 30% ethanol ([@B19]). Subsequently, the study of [@B18] further confirmed that HAR (20 mg/kg) could ameliorate impaired memory of scopolamine-induced mice by cholinergic functions enhancement through inhibiting AChE. Nevertheless, the most recent research indicated that HAR was not only a substrate of multidrug resistance-associated protein isoform 2 (MRP2), but also had a weak metabolic stability, and eventually led to substantially lower bioavailability than that of HAL in different animals ([@B34]). Thus, it is speculated that the effective dosage of HAL against AD may be far lower than HAR. Therefore, a systematic comparison study on the anti-amnesic effects and mechanisms of the two analogs should be conducted to seek a preferable candidate compound for AD therapy.

In the current study, the modulatory effects of HAL and HAR on the scopolamine-induced memory impairments were compared using the behavioral assessment in Morris water maze (MWM). MWM has been extensively used in the study of the neurobiology and neuropharmacology of spatial learning and memory, and which plays an important role in the validation of rodent models for neurocognitive disorders such as AD ([@B8]). Furthermore, the biochemical assays, western blotting as well as immunofluorescence analysis were comprehensively performed to clarify the possible effects of HAL and HAR on some underlying mechanisms involved in AD progressions. The results of the present study will be beneficial for evaluating the anti-amnesic effects of β-carboline alkaloids in further research and development, and could provide valuable information for clinical treatment of AD.

Materials and Methods {#s1}
=====================

Materials
---------

Harmaline, HAR, [L]{.smallcaps}-tryptophan ([L]{.smallcaps}-Trp), 5-hydroxytryptamine (5-HT), 5-hydroxyindole-3-acetic acid (5-HIAA), acetylcholine chloride (ACh), choline chloride (Ch), γ-aminobutyric acid (γ-GABA), [L]{.smallcaps}-glutamic acid monosodium salt monohydrate ([L]{.smallcaps}-Glu), [L]{.smallcaps}-phenylalanine ([L]{.smallcaps}-Phe), [L]{.smallcaps}-tyrosine ([L]{.smallcaps}-Tyr), theophylline \[Theo, internal standard (IS)\] and all other chemicals used were purchased from Sigma-Aldrich, Co., Ltd. (St. Louis, MO, United States). Scopolamine hydrobromide and donepezil hydrochloride monohydrate were purchased from TCI (Shanghai) Development, Co., Ltd. (Shanghai, China). Carboxymethylcellulose sodium (CMC-Na) and NaCl were obtained from Meilunbio^®^ Biotech, Co., Ltd. (Dalian, China). Compound titanium dioxide colorant was purchased from Shanghai Dyestuffs Research Institute, Co., Ltd. (Shanghai, China). The BCA protein quantification kit, RIPA lysis buffer, bovine serum albumin (BSA), PBST (10X), 30% acrylic amide, 10% SDS, glycine, sample loading buffer (4X) and TEMED were purchased from YEASEN Biotechnology, Co., Ltd. (Shanghai, China). Phospholipase inhibitor and protease inhibitor were purchased from Roche Applied Science (Foster City, CA, United States). PVDF membrane and Immobilon^TM^ Western chemiluminescent HRP substrate were purchased from Millipore (Billerica, MA, United States). Rabbit anti-AChE, rabbit anti-choline acetyltransferase (ChAT), rabbit anti-MPO and anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH), HRP-conjugated anti-rabbit IgG antibodies, and marker were purchased from Abcam Technology (Cambridge, MA, United States). Acetonitrile, methanol, and formic acid of HPLC grade were purchased from Fisher Scientific, Co. (Santa Clara, CA, United States). Deionized water (\>18 mΩ) was purified by Milli-Q Academic System (Millipore, Corp., Billerica, MA, United States). All other chemicals were of analytical grade.

Animals
-------

One hundred and eight male C57BL/6 mice (aged 10 weeks) were obtained from Drug Safety Evaluation and Research Center of Shanghai University of Traditional Chinese Medicine. Mice were raised in a well-lighted air-conditioned room (25 ± 1°C) under standard environmental conditions (relative humidity: 60--65%, 12 h light--dark cycles: light on from 7:00 to 19:00) and given free access to rodent chow and tap water. All animal-use procedures were in accordance with the regulations for animal experimentation issued by the State Committee of Science and Technology of the China on 14 November 1988 and approved by the Experimental Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine (No. SUTCM-2011-1107; Approval date: 10 November, 2011).

Drug Administration
-------------------

Based on the difference in the bioavailability of HAL and HAR, the dosages were set to 2, 5, and 10 mg/kg for HAL, and 10, 20, and 30 mg/kg for HAR ([@B59]; [@B50]). One hundred and eight mice were randomly divided into nine groups (12 mice per group), namely, control group (vehicle, 0.5% CMC-Na), scopolamine group (1 mg/kg), donepezil group (positive control, 5 mg/kg), HAL groups (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages), and HAR groups (10, 20, and 30 mg/kg, namely L, M, and H dosages). As shown in **Figure [1](#F1){ref-type="fig"}**, before MWM test, the control and scopolamine groups were oral administered with 0.5% CMC-Na solution, and HAL (L, M, and H dosages), HAR (L, M, and H dosages) and donepezil (5 mg/kg) groups were administered by *gavage* for seven consecutive days. From day 8 to day 16, scopolamine (1 mg/kg) was intraperitoneally (i.p.) injected to all groups except the control group that received normal saline 30 min after the various treatments. Subsequently, the behavioral tests were daily performed 30 min after the i.p. injection of scopolamine or normal saline.

![The time schedule of the experimental and treatment designs of mice.](fphar-09-00346-g001){#F1}

Behavioral Assessment in Morris Water Maze
------------------------------------------

The MWM test was applied to evaluate the effects of HAL and HAR on mice spatial learning and memory as previously described by Richard Morris in 1982 with minor modifications ([@B43]; [@B18]; [@B51]).

The MWM equipment consisted of a white circular water tank (diameter: 120 cm and height: 50 cm) surrounded by various visual cues (star, square, rectangle, and circle, etc.) on the pillars in fixed positions during the entire experiment. The tank was whitened by addition of non-toxic colorant, compound titanium dioxide, at 22 ± 2°C so that the platform was invisible under the water surface. The tank was virtually separated into four equal quadrants, including the Southeast, Northeast, Southwest, and Northwest. A white platform (diameter: 10 cm and height: 25 cm) was centered in the Southwest quadrant ([@B23]; [@B27]; [@B40]). The whole experimental procedure was composed of adaptive training (1 day, once a day), visible platform test (1 day, four trials a day), hidden platform tests (5 days, four trials a day), and spatial probe trial (24 h after the last hidden platform test, once a day).

For the adaptive training (1 day, once a day), the first day of the MWM test (day 8 of drug treatments), each mouse was placed inside the water tank to swim for 60 s to receive an acclimatization session. The next day (day 9 of drug treatments), in order to investigate the visual, sensory, and motor of mice, the visible platform was positioned 1 cm above the water surface, and each mouse was allowed to find the platform in 60 s. The test (1 day, four trials a day) was performed prior to the hidden platform trial to screen the qualified mice. Subsequently, the platform was submerged 1 cm below the water surface in hidden platform tests (5 days, four trials a day, days 10--14 of drug treatments). The swimming activity was recorded by a video camera overhead and analyzed via a computerized tracking and image analyzer system (RD1101-MWM-G, Shanghai Mobile Datum Information Technology Company, Shanghai, China). Mice were released into the tank with head facing the tank wall from one of four quadrants successively (the Northeast, North, East, and Southeast) and allowed to find the platform in 60 s. If the mouse failed to locate the platform, it should be gently guided by the specific experimenter, and allowed to stay for 15 s in the platform. After each trial, each mouse was taken to its cage and allowed to dry under a heater. The escape latency and the escape rate were recorded for each trial. In spatial probe trial (day 15 of drug treatments), the platform was removed from the tank. Each mouse was placed into the water tank from the quadrant (for instant, the Northwest) opposite from the previous platform location (target quadrant) to receive 60 s memory retention test ([@B30]; [@B38]; [@B42]). The time in target quadrant and crossing number were recorded.

Collection of Brain Tissues
---------------------------

On the 16th day after drug treatments, all the mice were anesthetized and plasma was collected by ophthalmectomy, and then brain tissues were collected after decapitation. In each group, the brains of a sub set of animals were used for immunofluorescence analysis and the others for biochemical and western blotting analysis. After sacrifices, the brain tissues were excised immediately, rinsed with normal saline, blotted surface water moisture with filter paper, and weighed. The cortex and hippocampus of each brain were divided into two parts (left and right) on ice, respectively. Some of them were fixed with 4% paraformaldehyde for immunofluorescence analysis, and the others were frozen immediately by liquid nitrogen and then stored at -80°C until analysis.

Biochemical Assay
-----------------

The cortex and hippocampus were homogenized in the ice-cold 0.1 M phosphate buffer (pH 7.4), and the 10% (w/v) homogenates were centrifuged at 4°C at 12,000 rpm for 10 min, and the supernatants were separated and then stored at -80°C for biochemical estimation ([@B42]). The levels of AChE, ChAT, superoxide dismutase (SOD), glutathione peroxidase (GSH-px), maleic diadehyde (MDA), MPO, tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), interleukin 6 (IL-6), interleukin 10 (IL-10), and nitric oxide (*NO*) in the cerebral cortex and/or hippocampus homogenates were determined by ELISA using commercially available assay kits (Jiancheng, Nanjing, China) according to the manufacturer's protocols. Particularly, the levels of the above biochemical factors in the cerebral cortex and hippocampus were normalized using the protein concentration of each sample. Assays were performed in duplicate.

Western Blotting Analysis
-------------------------

The cortex and hippocampus were homogenized in the ice-cold 50 mM Tris-HCl buffer (pH 7.4) containing phosphatase inhibitor and protease inhibitor. After centrifugation (12,000 rpm) for 10 min at 4°C, the total protein content was determined by BCA protein assay kit. The protein samples were mixed with a quarter volume of loading buffer, and then heated for 5 min at 100°C. 20 μg protein of each sample was electrophoresed by an 8% SDS-PAGE and transferred to PVDF membranes. Afterward, the membrane was blocked for 1 h by 5% non-fat milk at room temperature and incubated with anti-GAPDH (1:5000), anti-AChE (1:1000), anti-ChAT (1:1000), and anti-MPO (1:1000) at 4°C overnight. Subsequently, the membranes were thoroughly rinsed with PBST and then incubated with HRP-conjugated anti-rabbit (1:5000) secondary antibody for 2 h at room temperature. Following completely washing with PBST, the protein bands were visualized with ECL prime kit.

Immunofluorescence Analysis
---------------------------

Myeloperoxidase generation was visualized by immunofluorescence microscopy as described previously with minor changes ([@B17]). After fixing in 4% paraformaldehyde, the cortices were cut into 5 μm thick sagittal sections, and were deparaffinized and processed for immunofluorescence analysis. Brain sections were placed in a citric acid (pH 6.0) solution for antigen repair in a microwave oven. Subsequently, the autofluorescence quenching was carried out for 5 min. After blocking in 2% BSA, the sections were probed with anti-MPO (1:100) overnight at 4°C. Afterward, the sections were washed with PBS (pH 7.4) for three times and incubated with HRP-conjugated anti-rabbit (1:300) secondary antibody for 30 min at room temperature. Then, 4′,6-diamidino-2-phenylindole (DAPI) was employed for DNA counterstaining and the brain sections were observed under a fluorescence microscope (Nikon ECLIPSE C1, Japan), and the images were captured accordingly. Here, the fluorescence of DAPI or MPO was measured at an excitation wavelength of 330--380 or 510--560 nm and an emission wavelength of 420 or 590 nm, respectively.

Effects of HAL and HAR on the Neurotransmitters
-----------------------------------------------

### Extraction Procedure

A rapid, reliable and convenient precipitation method was applied to prepare the cerebral cortex homogenates and plasma samples. A 100 μL sample was added with 200 μL ice-cold acetonitrile containing 60 ng/mL IS in a 1.5 mL centrifuge tube and vortex-mixed for 1 min. The mixture was then centrifuged at 12,000 rpm for 10 min (4°C). A 5 μL aliquot of the supernatant from each sample was injected into ultra performance liquid chromatography combined with electrospray ionization (ESI) quadrupole tandem mass spectrometry (UPLC-ESI-MS/MS) for quantitative analysis.

### UPLC-ESI-MS/MS Analysis

The concentrations of various neurotransmitters were simultaneous quantified with SHIMADZU LC-30AD UPLC system (Shimadzu, Kyoto, Japan) connected to an AB Sciex QTRAP^®^ 6500 triple quadrupole mass spectrometer (SCIEX, United States) equipped with an ESI source using positive ion detection mode for multiple reaction monitoring. Chromatographic separation was conducted using a ZIC-cHILIC column (150 mm × 2.1 mm, 3 μm, Merck-Sequant, Germany) with a SeQuant ZIC-cHILIC guard column (20 mm × 2.1 mm, 5 μm, Merck-Sequant, Germany). The mobile phase, acetonitrile-water (65:35, v/v) containing 0.1% formic acid was delivered at a flow rate of 0.2 mL/min. To protect the mass spectrometer from contaminations, the flow was diverted to waste during the first minute after injection. All other instrumental parameters were set according to our previous study ([@B24]). The UPLC-ESI-MS/MS method was well-validated and was successfully applied to determine the concentrations of neurotransmitters in the cerebral cortex homogenates and plasma ([@B24]).

Statistical Analysis
--------------------

Statistical evaluation was carried out with SPSS version 18.0 software, and the data were expressed as the mean ± SD. The presented escape latency and path length data in MWM test were analyzed by repeated measures two-way ANOVA. The other behavioral data and the biomarkers changes *in vitro* were tested by one-way ANOVA for multiple comparisons. Significant results were marked according to conventional critical *P*-values: ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.

Results
=======

HAL and HAR Attenuated Cognitive Dysfunction of Scopolamine-Treated Mice in MWM
-------------------------------------------------------------------------------

To determine the effects of HAL (L, M, and H dosages) and HAR (L, M, and H dosages) on spatial learning and memory, the MWM task was carried out in the scopolamine-induced memory impairment mice. Two-way repeated measures analysis with mixed model showed that the latency to reach the platform was significantly different among the experimental groups of mice (*F*~(8,396)~ = 26.011, *P* \< 0.001) and days of acquisition training (*F*~(4,396)~ = 15.274, *P* \< 0.001). There was no significant interaction between groups and days (*F*~(32,396)~ = 1.132, *P* \> 0.05), suggesting that the differences among groups were dependent on the treatment. As presented in **Figure [2](#F2){ref-type="fig"}**, in the hidden platform testing, the escape latency and path length in scopolamine-induced group were significantly longer than those of the control group on the fourth (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 3.135, *P* \< 0.01; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.074, *P* \< 0.01) and fifth days (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.164, *P* \< 0.01; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.548, *P* \< 0.01), indicating the successfully-constructed mice model of memory impairment. However, the scopolamine-induced cognitive deficits were reversed by both HAL and HAR. Compared with scopolamine-induced group, the escape latency and path length were effectively reduced in HAL (L, M, and H dosages) and HAR (M and H dosages) treated groups on the fourth (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.975, *P* \< 0.01; *F*~(8,99)~ = 2.816, *P* \< 0.05; *F*~(8,99)~ = 2.795, *P* \< 0.05; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 3.836, *P* \< 0.01; *F*~(8,99)~ = 3.231, *P* \< 0.01; *F*~(8,99)~ = 2.658, *P* \< 0.05; **Figure [2C](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.673, *P* \< 0.01; *F*~(8,99)~ = 4.881, *P* \< 0.01; **Figure [2D](#F2){ref-type="fig"}**, *F*~(8,99)~ = 3.817, *P* \< 0.01; *F*~(8,99)~ = 3.129, *P* \< 0.01) and fifth days (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 12.637, *P* \< 0.001; *F*~(8,99)~ = 2.802, *P* \< 0.05; *F*~(8,99)~ = 2.772, *P* \< 0.05; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.014, *P* \< 0.01; *F*~(8,99)~ = 2.722, *P* \< 0.05; *F*~(8,99)~ = 2.531, *P* \< 0.05; **Figure [2C](#F2){ref-type="fig"}**, *F*~(8,99)~ = 4.574, *P* \< 0.01; *F*~(8,99)~ = 4.632, *P* \< 0.01; **Figure [2D](#F2){ref-type="fig"}**, *F*~(8,99)~ = 2.547, *P* \< 0.05; *F*~(8,99)~ = 3.905, *P* \< 0.01). Howbeit, when treated with the low dosage of HAR at 10 mg/kg (L dosage group), no significantly decrease in the escape latency and path length throughout the training period on the fourth (**Figure [2C](#F2){ref-type="fig"}**, *F*~(8,99)~ = 1.182, *P* \> 0.05; **Figure [2D](#F2){ref-type="fig"}**, *F*~(8,99)~ = 0.494, *P* \> 0.05) and fifth days (**Figure [2C](#F2){ref-type="fig"}**, *F*~(8,99)~ = 0.873, *P* \> 0.05; **Figure [2D](#F2){ref-type="fig"}**, *F*~(8,99)~ = 0.201, *P* \> 0.05). It also can be seen from **Figure [2](#F2){ref-type="fig"}**, the escape latency and path length of donepezil-treated (5 mg/kg) were markedly shortened compared with those of the scopolamine-induced group on the fourth (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 2.668, *P* \< 0.05; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 2.643, *P* \< 0.05) and fifth days (**Figure [2A](#F2){ref-type="fig"}**, *F*~(8,99)~ = 2.780, *P* \< 0.05; **Figure [2B](#F2){ref-type="fig"}**, *F*~(8,99)~ = 2.897, *P* \< 0.05) during training trial session three.

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on scopolamine-induced memory impairments mice. HAL (L, M, and H dosages), HAR (L, M, and H dosages), and donepezil (5 mg/kg) were administered by *gavage* for 7 days prior to the training for Morris water maze (MWM) tests, and continued during the testing. Memory impairments were induced by scopolamine (1 mg/kg, i.p.). The escape latency **(A)** and path length **(B)** of HAL (L, M, and H dosages) treated groups in hidden platform tests for five consecutive days, and the escape latency **(C)** and path length **(D)** of HAR (L, M, and H dosages) treated groups in hidden platform tests for five consecutive days. The error bar (SD) for data points in this figure was not given in order to clearly discriminate the difference among treatments. *N* = 12/group. ^\#\#^*P* \< 0.01, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g002){#F2}

On the day after the hidden platform testing, the spatial probe trial was conducted by taking the platform away to evaluate the spatial memory of all mice. As shown in **Figure [3](#F3){ref-type="fig"}**, the passing frequency was remarkably declined in the scopolamine-induced group (*F*~(8,81)~ = 5.498, *P* \< 0.05), illustrating that 1 mg/kg of scopolamine damaged the formation of spatial memory in mice. Particularly, apart from HAR (L dosage) treatment group (*F*~(8,81)~ = 0.494, *P* \> 0.05), the other treatment groups of HAL (L, M, and H dosages) and HAR (M and H dosages) dramatically raised the passing frequency (*F*~(8,81)~ = 11.667, *P* \< 0.01; *F*~(8,81)~ = 9.072, *P* \< 0.01; *F*~(8,81)~ = 4.507, *P* \< 0.05; *F*~(8,81)~ = 7.063, *P* \< 0.05; *F*~(8,81)~ = 8.583, *P* \< 0.01, respectively), and the increase of HAL-L dosage group was more notable compared to the other groups (**Figure [3](#F3){ref-type="fig"}**). Besides, donepezil-treated (5 mg/kg) group also significantly increased the passing frequency in comparison with the scopolamine-induced mice (**Figure [3](#F3){ref-type="fig"}**, *F*~(8,81)~ = 5.345, *P* \< 0.05). All these results suggested that HAL (L, M, and H dosages) and HAR (M and H dosages) could ameliorate the spatial memory ability of scopolamine-induced cognitive dysfunction mice, and HAL exhibited stronger effects than HAR on the spatial learning and memory in MWM.

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on scopolamine-induced memory impairments mice. The frequency of mice passing through the platform location **(A)**, and the swimming tracks of mice in water tank **(B)**. The green circle indicates the location of the hidden platform, while the red curves represent the tracks of mice movement. *N* = 10/group. ^\#^*P* \< 0.05, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; *vs.* the scopolamine-induced group.](fphar-09-00346-g003){#F3}

Effects of HAL and HAR on Scopolamine-Induced Cholinergic System, Oxidative Stress, and Inflammation
----------------------------------------------------------------------------------------------------

To further elucidate the potential mechanisms of HAL and HAR in improving memory induced by scopolamine, the levels of multifarious biochemical factors and protein expressions associated with the cholinergic system, oxidative stress, and inflammation were investigated. **Figures [4](#F4){ref-type="fig"}**, **[5](#F5){ref-type="fig"}** present the changes of various biochemical factors in the cortex or hippocampus, and **Figures [6](#F6){ref-type="fig"}**--**[8](#F8){ref-type="fig"}** give the effects of HAL and HAR on the protein expressions in the cortex of mice.

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the activities of acetylcholinesterase (AChE), choline acetyltransferase (ChAT), and myeloperoxidase (MPO) in the cerebral cortex **(A--C)** and hipocampus **(D--F)** of scopolamine-induced cognitive impairments mice, respectively. Data were expressed as the mean ± SD (*n* = 10). ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g004){#F4}

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the activity or production of superoxide dismutase (SOD) **(A)**, glutathione peroxidase (GSH-px) **(B)**, maleic diadehyde (MDA) **(C)**, tumor necrosis factor α (TNF-α) **(D)** and nitric oxide (*NO*) **(E)** in the cerebral cortex of scopolamine-induced cognitive impairments mice, respectively. Data were expressed as the mean ± SD (*n* = 10). ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001, *vs.* the control group. Interleukin 1β (IL-1β) **(F)**, interleukin 6 (IL-6) **(G)** and interleukin 10 (IL-10) **(H)**. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g005){#F5}

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the protein expression levels of acetylcholinesterase (AChE), and choline acetyltransferase (ChAT) in the cerebral cortex **(A,C,E)** and hipocampus **(B,D,F)** of scopolamine-induced cognitive impairments mice. Data were expressed as the mean ± SD (*n* = 3). ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g006){#F6}

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the protein expression levels of myeloperoxidase (MPO) in the cerebral cortex **(A,C)** and hipocampus **(B,D)** of scopolamine-induced cognitive impairments mice. Data were expressed as the mean ± SD (*n* = 3). ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g007){#F7}

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the generation of myeloperoxidase (MPO) in the cerebral cortex of scopolamine-induced cognitive impairments mice visualized by immunofluorescence microscopy.](fphar-09-00346-g008){#F8}

Effects of HAL and HAR on Cholinergic Deficits
----------------------------------------------

To clarify the effects of HAL and HAR on the cerebral cholinergic function, the changes in the activities and protein levels of AChE and ChAT in the cortical and hippocampal tissues of all mice were assessed. As shown in **Figures [4A,D](#F4){ref-type="fig"}**, treatment with scopolamine at 1 mg/kg significantly increased the activity of AChE in the cortex and hippocampus (*F*~(8,81)~ = 10.553, *P* \< 0.01; *F*~(8,81)~ = 6.177, *P* \< 0.05). Except HAR-L dosage group in the cortex, the other HAL (L, M, and H dosages) and HAR (M and H dosages) treatment groups considerably reduced the AChE activity (**Figure [4A](#F4){ref-type="fig"}**, *F*~(8,81)~ = 10.837, *P* \< 0.01; *F*~(8,81)~ = 8.621, *P* \< 0.05; *F*~(8,81)~ = 15.177, *P* \< 0.01; *F*~(8,81)~ = 8.615, *P* \< 0.05; *F*~(8,81)~ = 16.330, *P* \< 0.001; **Figure [4D](#F4){ref-type="fig"}**, *F*~(8,81)~ = 46.593, *P* \< 0.001; *F*~(8,81)~ = 34.179, *P* \< 0.001; *F*~(8,81)~ = 7.968, *P* \< 0.05; *F*~(8,81)~ = 4.769, *P* \< 0.05; *F*~(8,81)~ = 49.802, *P* \< 0.001; *F*~(8,81)~ = 46.665, *P* \< 0.001). Likewise, donepezil-treated group evidently lessened the activities of AChE compared with the levels in the scopolamine-induced group (**Figure [4A](#F4){ref-type="fig"}**, *F*~(8,81)~ = 13.138, *P* \< 0.01; **Figure [4D](#F4){ref-type="fig"}**, *F*~(8,81)~ = 7.400, *P* \< 0.05). Additionally, the scopolamine-induced group displayed a significant decrease in the activity of ChAT in both cortex and hippocampus (**Figure [4B](#F4){ref-type="fig"}**, *F*~(8,81)~ = 5.481, *P* \< 0.05; **Figure [4E](#F4){ref-type="fig"}**, *F*~(8,81)~ = 4.874, *P* \< 0.05). Nevertheless, HAL (L and M dosages) and HAR (M and H dosages) administrations appreciably increased the ChAT activity in the cortex (**Figure [4B](#F4){ref-type="fig"}**, *F*~(8,81)~ = 7.956, *P* \< 0.05; *F*~(8,81)~ = 8.390, *P* \< 0.05; *F*~(8,81)~ = 7.835, *P* \< 0.05; *F*~(8,81)~ = 51.927, *P* \< 0.001), and the ChAT levels of all HAL and HAR treatment groups in the hippocampus were significantly higher than those in the scopolamine-induced group (**Figure [4E](#F4){ref-type="fig"}**, *F*~(8,81)~ = 18.139, *P* \< 0.001; *F*~(8,81)~ = 9.665, *P* \< 0.01; *F*~(8,81)~ = 14.113, *P* \< 0.01; *F*~(8,81)~ = 5.178, *P* \< 0.05; *F*~(8,81)~ = 7.599, *P* \< 0.05; *F*~(8,81)~ = 11.953, *P* \< 0.01), and the effect of HAL-L dosage group on the ChAT activity was more significant in comparison with HAR administration groups.

As depicted in **Figure [6](#F6){ref-type="fig"}**, compared to the control group, the protein expression levels of AChE in cerebral cortex and hippocampus of scopolamine-induced group were prominently increased (**Figure [6C](#F6){ref-type="fig"}**, *F*~(8,18)~ = 36.632, *P* \< 0.01; **Figure [6D](#F6){ref-type="fig"}**, *F*~(8,18)~ = 14.823, *P* \< 0.05), while the protein levels of ChAT were almost unchanged (**Figures [6E,F](#F6){ref-type="fig"}**). Following treatments with HAL (L, M, and H dosages), HAR (M and H dosages) and donepezil, except for HAR (L dosage), the protein levels of AChE in the cortex were reduced markedly compared with scopolamine-induced group (**Figure [6C](#F6){ref-type="fig"}**, *F*~(8,18)~ = 50.590, *P* \< 0.001; *F*~(8,18)~ = 16.950, *P* \< 0.05; *F*~(8,18)~ = 30.993, *P* \< 0.01; *F*~(8,18)~ = 23.821, *P* \< 0.01; *F*~(8,18)~ = 52.196, *P* \< 0.001; *F*~(8,18)~ = 29.284, *P* \< 0.01), while the levels of ChAT were not altered (**Figure [6E](#F6){ref-type="fig"}**). And similar effects on the levels of AChE and ChAT were seen with HAL and HAR (L, M, and H dosages) administrations in the hippocampus (**Figure [6D](#F6){ref-type="fig"}**, *F*~(8,18)~ = 41.195, *P* \< 0.001; *F*~(8,18)~ = 28.111, *P* \< 0.01; *F*~(8,18)~ = 47.611, *P* \< 0.001; *F*~(8,18)~ = 30.539, *P* \< 0.01; *F*~(8,18)~ = 33.225, *P* \< 0.01; *F*~(8,18)~ = 40.032, *P* \< 0.001; **Figure [6F](#F6){ref-type="fig"}**). In addition, the inhibitory effects of HAR on the AChE protein expression were dose-dependent, while HAL had a notable inhibitory effect at low dose of 2 mg/kg (**Figure [6](#F6){ref-type="fig"}**). Thus, HAL and HAR treatments prevented against scopolamine-induced elevation of the AChE activity and protein expression and reduction of the ChAT activity, which demonstrated that HAL and HAR could enhance the function of cholinergic system, and alleviate the behavioral dysfunction. In particular, HAL manifested a significant improvement under low dosage.

Effects of HAL and HAR on Oxidative Stress Markers
--------------------------------------------------

The effects of HAL and HAR on the activities of antioxidant enzymes SOD, GSH-px, and the level of MDA in the cortex were measured. As **Figure [5](#F5){ref-type="fig"}** indicated, the scopolamine-induced group visibly attenuated the SOD and GSH-px activities compared to the control group (**Figure [5A](#F5){ref-type="fig"}**, *F*~(8,81)~ = 12.254, *P* \< 0.01; **Figure [5B](#F5){ref-type="fig"}**, *F*~(8,81)~ = 4.577, *P* \< 0.05). Whereas, HAL (H dosage), HAR (M and H dosages), and donepezil administrations significantly increased the SOD activity (**Figure [5A](#F5){ref-type="fig"}**, *F*~(8,81)~ = 13.287, *P* \< 0.01; *F*~(8,81)~ = 13.424, *P* \< 0.01; *F*~(8,81)~ = 34.510, *P* \< 0.001; *F*~(8,81)~ = 8.670, *P* \< 0.01), and HAL, HAR (both H dosages) and donepezil treatments clearly raised the activity of GSH-px (**Figure [5B](#F5){ref-type="fig"}**, *F*~(8,81)~ = 6.010, *P* \< 0.05; *F*~(8,81)~ = 6.008, *P* \< 0.05; *F*~(8,81)~ = 6.860, *P* \< 0.05). Furthermore, with HAL, HAR (both M and H dosages) and donepezil (5 mg/kg) treatments, the significant attenuation of MDA level increase was observed compared with the scopolamine-induced mice (**Figure [5C](#F5){ref-type="fig"}**, *F*~(8,81)~ = 9.302, *P* \< 0.01; *F*~(8,81)~ = 6.565, *P* \< 0.05; *F*~(8,81)~ = 12.690, *P* \< 0.01; *F*~(8,81)~ = 33.627, *P* \< 0.001; *F*~(8,81)~ = 5.874, *P* \< 0.05). These results suggested that HAL and HAR may prevent against scopolamine-induced oxidative damage through protecting the cortex from oxidative stress. Noticeably, the oxidative damage could be improved only at high dosages for both HAL and HAR, and the improvements of HAL and HAR were comparable in general.

Effects of HAL and HAR on Inflammation Levels
---------------------------------------------

The effects of HAL and HAR on the activities of inflammatory factors MPO, TNF-α, IL-1β, IL-6, IL-10 and the level of *NO* in the cortex or hippocampus were analyzed. The activities of MPO (cortex and hippocampus) and TNF-α (cortex) were elevated in the scopolamine-induced mice compared to the control mice (**Figure [4C](#F4){ref-type="fig"}**, *F*~(8,81)~ = 34.740, *P* \< 0.001; **Figure [4F](#F4){ref-type="fig"}**, *F*~(8,81)~ = 6.729, *P* \< 0.05; **Figure [5D](#F5){ref-type="fig"}**, *F*~(8,81)~ = 6.316, *P* \< 0.05), but the levels of IL-1β, IL-6, and IL-10 were not changed (**Figures [5F](#F5){ref-type="fig"}--[H](#F5){ref-type="fig"}**). However, HAL, HAR (both M and H dosages) and donepezil administrations resulted in a significant reduction of the MPO activity in the cortex and hippocampus in a dose dependent manner (**Figure [4C](#F4){ref-type="fig"}**, *F*~(8,81)~ = 10.435, *P* \< 0.01; *F*~(8,81)~ = 32.309, *P* \< 0.001; *F*~(8,81)~ = 16.397, *P* \< 0.01; *F*~(8,81)~ = 31.291, *P* \< 0.001; *F*~(8,81)~ = 7.129, *P* \< 0.05; **Figure [4F](#F4){ref-type="fig"}**, *F*~(8,81)~ = 7.212, *P* \< 0.05; *F*~(8,81)~ = 10.533, *P* \< 0.01; *F*~(8,81)~ = 9.150, *P* \< 0.01; *F*~(8,81)~ = 18.903, *P* \< 0.001; *F*~(8,81)~ = 11.641, *P* \< 0.01), and HAL (L, M, and H dosages), HAR (M and H dosages) and donepezil treatments also weaken the activity of TNF-α in the cortex (**Figure [5D](#F5){ref-type="fig"}**, *F*~(8,81)~ = 10.377, *P* \< 0.01; *F*~(8,81)~ = 28.257, *P* \< 0.001; *F*~(8,81)~ = 31.088, *P* \< 0.001; *F*~(8,81)~ = 15.966, *P* \< 0.001; *F*~(8,81)~ = 23.530, *P* \< 0.001; *F*~(8,81)~ = 5.909, *P* \< 0.05). In addition, apart from HAR-L dosage group, a noticeable attenuation of *NO* level increase was found in the other HAL, HAR, and donepezil treatment mice compared with the scopolamine-induced amnesia mice (**Figure [5E](#F5){ref-type="fig"}**, *F*~(8,81)~ = 21.319, *P* \< 0.001; *F*~(8,81)~ = 12.996, *P* \< 0.01; *F*~(8,81)~ = 11.911, *P* \< 0.01; *F*~(8,81)~ = 5.227, *P* \< 0.05; *F*~(8,81)~ = 8.799, *P* \< 0.01; *F*~(8,81)~ = 17.349, *P* \< 0.001), and the inhibitory effects of HAL on TNF-α and *NO* were more pronounced than those of HAR.

As show in **Figure [7](#F7){ref-type="fig"}**, compared with the control mice, the protein expression levels of cortical and hippocampal MPO in scopolamine-induced mice were elevated (**Figure [7C](#F7){ref-type="fig"}**, *F*~(8,18)~ = 29.975, *P* \< 0.01; **Figure [7D](#F7){ref-type="fig"}**, *F*~(8,18)~ = 32.014, *P* \< 0.01). Following administrations of donepezil, HAL, and HAR (L, M, and H dosages), the protein expressions of MPO were apparently dropped in the cortex and hippocampus compared with scopolamine-induced group. Besides, the results of immunofluorescence determination also revealed that HAL and HAR treatments could strikingly reduce the MPO expression of the cortex with a dose-dependent manner, and the inhibitions of HAL and HAR were comparable (**Figure [8](#F8){ref-type="fig"}**). All these findings implied that HAL and HAR could abate the scopolamine-induced inflammatory injury through inhibiting the cortex and hippocampus from inflammation.

Modulator Effects of HAL and HAR on the Neurotransmitters of Scopolamine-Treated Mice
-------------------------------------------------------------------------------------

Various plasmatic and cortical neurotransmitters were estimated using UPLC-ESI-MS/MS and the alterations are presented in **Figures [9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**, respectively. Based on the method for determination of neurotransmitters established previously, the contents of ACh, Ch, [L]{.smallcaps}-Trp, 5-HT, [L]{.smallcaps}-Glu, [L]{.smallcaps}-Phe, [L]{.smallcaps}-Tyr in the plasma and ACh, Ch, [L]{.smallcaps}-Trp, γ-GABA, [L]{.smallcaps}-Glu, [L]{.smallcaps}-Phe, [L]{.smallcaps}-Tyr in the cortex were above the lower limit of quantitation, and then all of them were successfully quantified.

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the contents of neurotransmitters in the plasma of scopolamine-induced cognitive impairments mice. *N* = 10/group. ACh **(A)**, Ch **(B)**, [L]{.smallcaps}-Trp **(C)**, 5-HT **(D)**, [L]{.smallcaps}-Glu **(E)**, [L]{.smallcaps}-Phe **(F)**, [L]{.smallcaps}-Tyr **(G)**. ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01; ^\#\#\#^*P* \< 0.001, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g009){#F9}

![The effects of HAL (2, 5, and 10 mg/kg, namely low: L, medium: M, and high: H dosages) and HAR (10, 20, and 30 mg/kg, namely L, M, and H dosages) on the contents of neurotransmitters in the cerebral cortex of scopolamine-induced cognitive impairments mice. *N* = 10/group. ACh **(A)**, Ch **(B)**, [L]{.smallcaps}-Trp **(C)**, γ-GABA **(D)**, [L]{.smallcaps}-Glu **(E)**, [L]{.smallcaps}-Phe **(F)**, [L]{.smallcaps}-Tyr **(G)**. ^\#^*P* \< 0.05; ^\#\#^*P* \< 0.01, *vs.* the control group. ^∗^*P* \< 0.05; ^∗∗^*P* \< 0.01; ^∗∗∗^*P* \< 0.001, *vs.* the scopolamine-induced group.](fphar-09-00346-g010){#F10}

After induction of scopolamine at the dosage of 1 mg/kg, the concentrations of ACh, [L]{.smallcaps}-Trp, 5-HT, [L]{.smallcaps}-Glu, and [L]{.smallcaps}-Phe were decreased in the plasma (**Figure [9A](#F9){ref-type="fig"}**, *F*~(8,81)~ = 11.453, *P* \< 0.01; **Figure [9C](#F9){ref-type="fig"}**, *F*~(8,81)~ = 23.137, *P* \< 0.001; **Figure [9D](#F9){ref-type="fig"}**, *F*~(8,81)~ = 7.359, *P* \< 0.05; **Figure [9E](#F9){ref-type="fig"}**, *F*~(8,81)~ = 55.531, *P* \< 0.001; **Figure [9F](#F9){ref-type="fig"}**, *F*~(8,81)~ = 6.330, *P* \< 0.05), whereas with no impact on [L]{.smallcaps}-Tyr (**Figure [9G](#F9){ref-type="fig"}**, *F*~(8,81)~ = 2.091, *P* \> 0.05). However, when treatments with HAL and HAR at high dosage, the contents of ACh and [L]{.smallcaps}-Glu were elevated (**Figures [9A,E](#F9){ref-type="fig"}**), and the contents of [L]{.smallcaps}-Trp were evidently raised with HAL (L, M, and H dosages) and HAR (M and H dosages) administrations in a dose-dependent manner (**Figure [9C](#F9){ref-type="fig"}**). Moreover, the HAL and HAR (M and H dosages) treated mice exhibited a significant elevation of 5-HT level compared to the scopolamine-induced mice (**Figure [9D](#F9){ref-type="fig"}**). But, the HAL and HAR administrations did not modulate the contents of [L]{.smallcaps}-Phe and [L]{.smallcaps}-Tyr (**Figures [9F,G](#F9){ref-type="fig"}**). Besides, HAL (H dosage) as well as HAR (M and H dosages) produced an effect on reducing the content of Ch in the plasma (**Figure [9B](#F9){ref-type="fig"}**).

Furthermore, **Figure [10](#F10){ref-type="fig"}** shows the variations of the neurotransmitters in the cerebral cortex. Following inducing of scopolamine, the contents of ACh, [L]{.smallcaps}-Trp, [L]{.smallcaps}-Glu, [L]{.smallcaps}-Phe, and [L]{.smallcaps}-Tyr were obviously decreased (**Figure [10A](#F10){ref-type="fig"}**, *F*~(8,81)~ = 11.296, *P* \< 0.01; **Figure [10C](#F10){ref-type="fig"}**, *F*~(8,81)~ = 10.979, *P* \< 0.01; **Figure [10E](#F10){ref-type="fig"}**, *F*~(8,81)~ = 7.216, *P* \< 0.05; **Figure [10F](#F10){ref-type="fig"}**, *F*~(8,81)~ = 10.340, *P* \< 0.01; **Figure [10G](#F10){ref-type="fig"}**, *F*~(8,81)~ = 6.834, *P* \< 0.05), while the contents of Ch and γ-GABA were significantly raised in the cortex compared to the control group (**Figure [10B](#F10){ref-type="fig"}**, *F*~(8,81)~ = 7.377, *P* \< 0.05; **Figure [10D](#F10){ref-type="fig"}**, *F*~(8,81)~ = 5.580, *P* \< 0.05). Nevertheless, the contents of ACh were observably elevated in HAL (L, M, and H dosages) and HAR (M and H dosages) groups, and the contents of [L]{.smallcaps}-Trp were notably raised in HAL (L, M, and H dosages) and HAR (H dosage) groups, and the amounts of [L]{.smallcaps}-Glu were also elevated at the high dosage of HAL and HAR groups (**Figures [10A,C,E](#F10){ref-type="fig"}**). In addition, the HAL (L, M, and H dosages) and HAR (H dosage) treatments resulted in an obvious decreasing of Ch and γ-GABA levels compared with the scopolamine-induced group (**Figures [10B,D](#F10){ref-type="fig"}**). However, different doses of HAL and HAR showed negligible effect on the decrease of [L]{.smallcaps}-Phe and [L]{.smallcaps}-Tyr induced by scopolamine (**Figures [10F,G](#F10){ref-type="fig"}**). Generally, the effects of HAL on the important plasmatic and cortical neurotransmitters were more prominent than those of HAR (**Figures [9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**).

Discussion
==========

Alzheimer's disease is a deadly progressive neurodegenerative disorder with increasing of aging population and lifetime expectancy, and it is urgent to find new drugs that can effectively treat AD ([@B27]). It is generally known that cholinergic hypofunction, oxidative stress, and neuroinflammation are one of the main characteristics of AD ([@B1]; [@B11]). Scopolamine is a non-selective antagonist of the muscarinic cholinergic receptor ([@B22]; [@B26]). Numerous studies have shown that scopolamine can impair the ability of learning and memory in humans and animal models, and scopolamine-induced AD model is widely used to study cognitive deficiency and screen for anti-AD drugs ([@B16]). Scopolamine leads to the cognitive deficits associated with a reduction of cholinergic neurotransmission, increased oxidative stress as well as elevated inflammation in the brain ([@B36]). Accordingly, drugs can efficaciously enhance cholinergic function and/or attenuate oxidative stress and inflammation, and may reverse the learning and memory impairments in scopolamine-induced AD mice, and will ultimately be valuable for the treatment of AD.

Previously, [@B18] proved that HAR could inhibit the AChE activity and significantly improved spatial learning and memory of cognitively impaired mice, including APP/PS1 transgenic and scopolamine-induced AD mice. In the present study, the memory ameliorating effects of HAL (2, 5, and 10 mg/kg) and HAR (10, 20, and 30 mg/kg) on scopolamine-induced mice were compared using MWM behavioral evaluation. Scopolamine (1 mg/kg) was verified to damage the spatial learning and memory ability of mice in MWM task, which was consistent with our previous studies ([@B18]; [@B38]). After treatments with HAL (L, M, and H dosages) and HAR (M and H dosages), the escape latency and path length were decreased and the passing frequency were increased effectively (**Figures [2](#F2){ref-type="fig"}**, **[3](#F3){ref-type="fig"}**), demonstrating that HAL and HAR administrations noticeably improved the learning and spatial memory of the scopolamine-induced mice, and the improvements of HAL were more significant than those of HAR.

In order to further clarify the underlying mechanism for improving learning and memory of HAL and HAR in the scopolamine-induced mice, the alterations of cholinergic system, oxidative stress, and inflammation were assessed. As reported in previous literatures ([@B1]; [@B35]; [@B11]), scopolamine i.p. injection led to an attenuation of cholinergic function, elevated oxidative stress and inflammation in current study. Donepezil is a representative symptomatic therapy for mild and moderate AD as an AChE inhibitor ([@B7]), and recent researches have revealed that it also can suppress inflammation and oxidative stress ([@B48]; [@B58]). In this study, donepezil (positive control) could effectively ameliorate these changes in scopolamine-induced mice and improved their learning and memory. Similar to their activities *in vitro* ([@B60]; [@B37]), HAL and HAR at different dosages not only reversed scopolamine-induced raise of AChE activity, but also resulted in the elevation of neurotransmitter ACh and decrease of Ch in the cerebral cortex, hippocampus or plasma (**Figures [4](#F4){ref-type="fig"}**, **[9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**). Moreover, the protein levels of cortical AChE were evidently inhibited by HAL and HAR (**Figures [6C,D](#F6){ref-type="fig"}**). As reported by [@B45], ChAT-positive neurons were significantly reduced by treatment with scopolamine. The present results indicated that HAL and HAR could reverse the decrease of ChAT activity induced by scopolamine (**Figures [4B,E](#F4){ref-type="fig"}**), while have no impact on the protein expressions of ChAT (**Figures [6E,F](#F6){ref-type="fig"}**), and it needs to be further proved. Hence, these confirmed that anti-amnesic effects of HAL and HAR on the cognition dysfunction induced by scopolamine probably associated with modification of cholinergic system (particularly AChE), and HAL demonstrated an obvious cholinergic improvement at low dosage (2 mg/kg).

Additionally, many studies have shown that increased oxidative stress is extensively considered as a prominent contributive risk factor in the development of AD ([@B14]; [@B40]). HAL and HAR might serve as endogenous antioxidants and were found to possess an antioxidant capacity by scavenging free radicals ([@B53]; [@B5],[@B6]). In this study, the overproduction of ROS (a product of lipid peroxidation, MDA) and reduction of antioxidant enzymes (SOD and GSH-px) were observed in the scopolamine-induced mice (**Figure [5](#F5){ref-type="fig"}**). However, HAL and HAR administrations observably activated the antioxidant enzymes of SOD and GSH-px and suppressed the formation of MDA in the cortex of the scopolamine-induced dementia mice (**Figure [5](#F5){ref-type="fig"}**), and then improved the ability of antioxidant defense, indicating the neuroprotective effects of HAL and HAR. Notably, the antioxidative effects of HAL and HAR were generally comparable.

Furthermore, there is growing evidence suggests that memory impairment is associated with increased neuroinflammation ([@B1]). According to the study of [@B4], HAL and HAR demonstrated a significant inhibition on MPO with the IC~50~ of 0.08 and 0.26 μM, respectively. Anti-inflammatory activity of HAR was achieved through inhibiting TNF-α and *NO* in lipopolysaccharide-stimulated mouse RAW264 and human THP-1 cells ([@B46]). Notably, the high levels of pro-inflammatory cytokines (TNF-α and MPO) and inflammatory mediator (*NO*) were detected in the brain of amnesia mice induced by scopolamine (**Figures [4](#F4){ref-type="fig"}**, **[5](#F5){ref-type="fig"}**). The current study confirmed that HAL and HAR treatments could simultaneously inhibit the generation of *NO* and the upregulation of TNF-α and MPO, and the inhibitory actions of HAL on TNF-α and *NO* were more apparent than those of HAR (**Figures [4](#F4){ref-type="fig"}**, **[5](#F5){ref-type="fig"}**). Besides, the results of western blotting and immunofluorescence analysis further evidence that the protein expression levels of MPO were prominently suppressed by HAL and HAR (**Figures [7](#F7){ref-type="fig"}**, **[8](#F8){ref-type="fig"}**), suggesting that the ability of HAL and HAR to counteract the memory deficits might be mediated by suppressing the inflammatory markers TNF-α, MPO, and *NO*.

As is well-known, AD is associated with inadequate levels of various neurotransmitters ([@B28]; [@B52]). Previous studies have reported that mice received scopolamine alone showed a considerably decrease in cholinergic system reactivity, as indicated by a decreased ACh level and an increased AChE activity along with a decreased ChAT activity ([@B31]). A transgenic animal model of AD demonstrated a falling Glu level ([@B44]), and the serum and plasma metabolomics also indicated a decrease of Trp, 5-HT, Glu, Phe, Tyr in AD model mice or patients ([@B54]; [@B15]; [@B57]; [@B9]; [@B32]). Correspondingly, our results proved that the scopolamine-induced dementia was accompanied by the decrease of ACh, [L]{.smallcaps}-Trp, 5-HT, [L]{.smallcaps}-Glu, [L]{.smallcaps}-Phe, [L]{.smallcaps}-Tyr and the elevation of Ch and γ-GABA, which is in agreement with the previous studies ([@B49]; [@B44]; [@B31]; [@B54]; [@B15]; [@B28]; [@B57]; [@B61]; [@B9]; [@B38]). Neurotransmitters play an important role in the brain circuit involved in many aspects of learning and memory, especially the cholinergic, serotonergic, glutametargic, and GABAergic neurotransmitters ([@B54]; [@B28]; [@B61]). It is noteworthy that, except for [L]{.smallcaps}-Phe and [L]{.smallcaps}-Tyr, the other alterations could be effectively reversed by both HAL and HAR administrations in the plasma and cortex, and the modulations of HAL were more striking than those of HAR (**Figures [9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**). Accordingly, the regulations of these neurotransmitters by HAL and HAR may be beneficial to enhance the learning and memory ability of dementia mice.

Generally speaking, HAL (2, 5, and 10 mg/kg) and HAR (20 and 30 mg/kg) showed an enhancement in cholinergic neurotransmission through suppressing AChE and inducing ChAT, enhancing antioxidant defense by increasing SOD and GSH-px activities and reducing MDA production, enhancing anti-inflammatory effects via lowering TNF-α, MPO and *NO*, and modulating the levels of critical neurotransmitters (ACh, Ch, [L]{.smallcaps}-Trp, 5-HT, γ-GABA, and [L]{.smallcaps}-Glu). Thus, HAL and HAR may act on the multiple targets as the therapeutics for AD. Furthermore, the regulations of HAL on the cholinergic function, inflammation and neurotransmitters were more notable than those of HAR, and HAL showed a similar antioxidant capacity with HAR. Particularly, the effective dosage of HAL (2 mg/kg) was far lower than that of HAR (20 mg/kg), which may be mainly due to the differences in the bioavailability and metabolic stability of the two drugs ([@B34]). Taken together, all these results revealed that compared to HAR, HAL may be a better candidate compound with superior anti-amnesic and pharmacokinetic characteristics for AD therapy.

Conclusion
==========

In summary, HAL and HAR could effectively ameliorate memory impairments in a scopolamine-induced mouse model via improvement of cholinergic system function, suppression of oxidative stress and inflammation damage, and modulation of vital neurotransmitters in dementia mice. Especially for HAL, the regulations on the cholinergic function, inflammation and neurotransmitters were more significant than those of HAR, and displayed a comparable antioxidant effect to HAR. Notably, the effective dosage of HAL (2 mg/kg) was far lower than that of HAR (20 mg/kg). The overall results indicate that HAL can be a superior candidate drug for treating learning and memory dysfunctions such as AD. Further evaluations must be undertaken on the anti-amnesic effects and molecular mechanisms of HAL, which will provide substantial initial evidence for the prevention and treatment of AD.
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